Analytical Data
-
Gene name
SETDB1
- Application
-
Alternative Names
SETDB1；ESET；KIAA0067；KMT1E；Histone-lysine N-methyltransferase SETDB1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q15047
-
Expression Region
1-397aa
-
AA Sequence
MSSLPGCIGLDAATATVESEEIAELQQAVVEELGISMEELRHFIDEELEKMDCVQQRKKQLAELETWVIQKESEVAHVDQLFDDASRAVTNCESLVKDFYSKLGLQYRDSSSEDESSRPTEIIEIPDEDDDVLSIDSGDAGSRTPKDQKLREAMAALRKSAQDVQKFMDAVNKKSSSQDLHKGTLSQMSGELSKDGDLIVSMRILGKKRTKTWHKGTLIAIQTVGPGKKYKVKFDNKGKSLLSGNHIAYDYHPPADKLYVGSRVVAKYKDGNQVWLYAGIVAETPNVKNKLRFLIFFDDGYASYVTQSELYPICRPLKKTWEDIEDISCRDFIEEYVTAYPNRPMVLLKSGQLIKTEWEGTWWKSRVEEVDGSLVRILFLVLFFSTILEAEVGGGGT
-
Molecular Weight
44.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SETDB1, or SET domain bifurcated 1, is a histone methyltransferase that plays a crucial role in the regulation of gene expression and chromatin dynamics. It is primarily known for its ability to tri-methylate histone H3 at lysine 9 (H3K9me3), a mark associated with transcriptional repression and heterochromatin formation. Dysregulation of SETDB1 has been implicated in various diseases, including cancer, where altered expression levels can lead to aberrant gene silencing and promotion of tumorigenesis. As a member of the SET domain family, SETDB1 is involved in epigenetic modifications that influence developmental processes and cellular differentiation. Research into SETDB1 has gained momentum due to its potential as a therapeutic target; understanding its structure and function could provide insights into the development of novel epigenetic drugs. Recent studies have utilized recombinant protein techniques to produce SETDB1, allowing for detailed biochemical analyses and the exploration of its substrate specificity, kinetics, and role in protein complexes. The ability to study SETDB1 in a controlled environment has enhanced our understanding of its mechanism of action and its contributions to the epigenetic landscape, further highlighting its importance in maintaining cellular homeostasis and its potential implications in therapeutics for various diseases associated with epigenetic dysregulation.
